Coya Therapeutics reported positive results from a Phase 2 trial of LD IL-2 for Alzheimer's at CTAD24. The study met primary and secondary endpoints, showing safety and efficacy. The q4wks dosing led to significant improvements in CSF Aβ42 levels.